Researchers at the Federal University of Rio Grande do Sul (UFRGS) in Porto Alegre have published findings in Nature Neuroscience that may fundamentally change our understanding of yerba mate's effects on the brain. The study demonstrates for the first time that specific compounds in Ilex paraguariensis — particularly a family of triterpene saponins called matesaponins — activate cellular autophagy pathways in neural tissue, a mechanism increasingly recognized as central to preventing neurodegenerative diseases.
Autophagy, literally "self-eating," is the process by which cells break down and recycle damaged or dysfunctional components, including the misfolded protein aggregates that characterize Alzheimer's disease (amyloid-beta and tau tangles) and Parkinson's disease (alpha-synuclein). When autophagy declines — as it naturally does with aging — these toxic proteins accumulate, driving neuronal death and cognitive decline.
The Discovery
The UFRGS team, led by neuroscientist Dr. Rafael Oliveira, exposed cultured human neurons to various mate-derived compounds at physiologically relevant concentrations — those that would realistically reach the brain after normal oral consumption. Matesaponin 1 and matesaponin 3 activated the AMPK-mTOR autophagy pathway with potency comparable to rapamycin, a pharmaceutical compound currently being investigated as an anti-aging drug, but without rapamycin's problematic immunosuppressive effects.
In a mouse model of early Alzheimer's disease, animals given mate extract daily for eight weeks showed 31 percent fewer amyloid plaques than controls. More importantly, they performed significantly better on spatial memory tasks — navigating mazes with accuracy comparable to healthy control mice of the same age. Brain tissue analysis revealed elevated levels of beclin-1 and LC3-II, molecular markers confirming that autophagy had been enhanced.
We were frankly astonished by the magnitude of the effect. We expected some autophagy activation based on the literature, but the degree of plaque clearance and functional memory preservation was beyond our initial hypothesis. This is not a cure — but it may be one of the most accessible forms of neuroprotection available.
Epidemiological Support
The laboratory findings align with epidemiological observations that have intrigued neuroscientists for years. Southern Brazil and Argentina — regions with the highest per-capita yerba mate consumption in the world — report lower age-adjusted rates of dementia compared to regions of similar genetic background but lower mate consumption. Previous studies had attributed this to confounding factors, but the UFRGS findings suggest a direct biological mechanism.
The researchers are now preparing a Phase I clinical trial with 200 participants aged 55 to 75, scheduled to begin in late 2026. The trial will test whether standardized mate extract supplements — calibrated to deliver specific doses of matesaponins — can measurably improve biomarkers of cognitive health over a 12-month period. If successful, it would represent one of the first dietary interventions to demonstrate a direct neuroprotective mechanism in humans.